DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts
DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts
复制标题
DOI:
10.1016/j.jdermsci.2008.03.003
复制
发表时间:
2008-09-01
影响因子:
4.6
通讯作者:
Yamashita, Shunichi
中科院分区:
文献类型:
--
作者:
Makino, Sachio;Mitsutake, Norisato;Yamashita, Shunichi
Background: Keloid is a benign dermal tumor characterized by proliferation of dermal fibroblasts and overproduction of extracellular matrix (ECM). Nuclear factor kappaB (NF-kappa B) plays an important role in regulation of inflammation, immune response and cell proliferation. Activation of the NF-kappa B pathway is thought to be closely linked to abnormal cell proliferation and ECM production in keloid fibroblasts.Objective: This study was set out to investigate the effects of a novel selective NF-kappa B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on keloid fibroblasts. Methods: Primary normal and keloid dermal fibroblasts were used for this study. NF-kappa B activity was assessed by DNA-binding assay and immunohistochemistry. The effect of DHMEQ was evaluated by cell viability, cell growth and type I collagen accumulation.Results: Basal NF-kappa B activity was constitutively elevated in keloid fibroblasts, indicating that this pathway is involved in keloid pathogenesis. DHMEQ markedly reduced cell proliferation and type I collagen accumulation in keloid fibroblasts.Conclusion: The inhibition of NF-kappa B by DHMEQ may be an attractive therapeutic approach for keloids. (c) 2008 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.